We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+3.64%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$74.9B
AUM Growth
+$9.23B
(+14%)
Cap. Flow
+$7.27B
Cap. Flow
% of AUM
9.7%
Top 10 Holdings %
Top 10 Hldgs %
32.66%
Holding
3,137
New
748
Increased
792
Reduced
857
Closed
654
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$3.04B |
| 2 |
Microsoft
MSFT
|
+$830M |
| 3 |
Amazon
AMZN
|
+$550M |
| 4 |
Johnson & Johnson
JNJ
|
+$483M |
| 5 |
Apple
AAPL
|
+$470M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$474M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$435M |
| 3 |
Vanguard S&P 500 ETF
VOO
|
+$428M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$371M |
| 5 |
Micron Technology
MU
|
+$275M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.7% |
| 2 | Consumer Discretionary | 13.75% |
| 3 | Healthcare | 12.4% |
| 4 | Financials | 7.81% |
| 5 | Industrials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1276
Brighthouse Financial
BHF
$3.67B
| $2.3M | ﹤0.01% |
53,070
-81,285
| -61% | -$3.75M |
|
|
UMH
1277
UMH Properties
UMH
$1.34B
| $2.3M | ﹤0.01% |
+143,829
| New | +$2.24M |
|
1278
Lumentum
LITE
$48.7B
| $2.29M | ﹤0.01% |
44,989
-60,057
| -57% | -$2.72M |
|
1279
Collegium Pharmaceutical
COLL
$1.18B
| $2.29M | ﹤0.01% |
+70,964
| New | +$2.46M |
|
1280
Genius Sports
GENI
$1.96B
| $2.28M | ﹤0.01% |
418,094
-107,700
| -20% | -$575K |
|
1281
iShares China Large-Cap ETF
FXI
$4.32B
| $2.26M | ﹤0.01% |
87,108
-68,392
| -44% | -$1.8M |
|
1282
MKS Inc
MKSI
$18.6B
| $2.26M | ﹤0.01% |
17,302
-30,358
| -64% | -$3.83M |
|
1283
Willdan Group
WLDN
$1.05B
| $2.25M | ﹤0.01% |
78,110
+27,009
| +53% | +$806K |
|
|
NLOP
1284
Net Lease Office Properties
NLOP
$178M
| $2.25M | ﹤0.01% |
91,467
+73,119
| +399% | +$1.73M |
|
1285
Karyopharm Therapeutics
KPTI
$160M
| $2.25M | ﹤0.01% |
172,058
-982
| -0.6% | -$16.3K |
|
|
TCOA.WS
1286
CALL
DELISTED
Zalatoris Acquisition Corp. Public warrants, each whole public warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
TCOA.WS
| $2.23M | ﹤0.01% |
200,000
-13,935
| -7% | -$801 |
|
1287
Humacyte
HUMA
$171M
| $2.23M | ﹤0.01% |
463,662
+450,031
| +3,302% | +$2.34M |
|
|
DAWN
1288
DELISTED
Day One Biopharmaceuticals
DAWN
| $2.22M | ﹤0.01% |
161,129
+26,958
| +20% | +$394K |
|
1289
Invesco QQQ Trust
QQQ
$442B
| $2.22M | ﹤0.01% |
4,633
-54,525
| -92% | -$24.5M |
|
1290
Pacific Biosciences
PACB
$447M
| $2.21M | ﹤0.01% |
1,611,300
+1,117,966
| +227% | +$2.26M |
|
1291
Backblaze
BLZE
$720M
| $2.21M | ﹤0.01% |
358,220
-46,835
| -12% | -$365K |
|
1292
8x8 Inc
EGHT
$276M
| $2.21M | ﹤0.01% |
993,859
-353,951
| -26% | -$861K |
|
|
BYNOW
1293
CALL
DELISTED
byNordic Acquisition Corporation Warrant
BYNOW
| $2.21M | ﹤0.01% |
195,362
| – | – |
|
1294
VanEck BDC Income ETF
BIZD
$1.63B
| $2.2M | ﹤0.01% |
128,614
+574
| +0.4% | +$9.66K |
|
1295
Kodak
KODK
$819M
| $2.2M | ﹤0.01% |
+408,332
| New | +$2.07M |
|
1296
Orthofix Medical
OFIX
$500M
| $2.19M | ﹤0.01% |
+165,357
| New | +$2.27M |
|
|
TRML
1297
DELISTED
Tourmaline Bio
TRML
| $2.19M | ﹤0.01% |
170,447
+31,029
| +22% | +$499K |
|
1298
iShares US Transportation ETF
IYT
$2.29B
| $2.19M | ﹤0.01% |
+33,478
| New | +$2.2M |
|
1299
Evolus
EOLS
$406M
| $2.19M | ﹤0.01% |
201,849
-16,451
| -8% | -$202K |
|
1300
NetEase
NTES
$82.8B
| $2.19M | ﹤0.01% |
+22,867
| New | +$2.18M |
|
Similar funds
Marshall Wace's Q2 2024 Portfolio in Review
As of Q2 2024, Marshall Wace held 3,137 positions worth $74.9B, up 14% from $65.7B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Marshall Wace deployed $7.27B of net new capital in Q2 2024, opening 748 new positions and adding to 792 existing holdings. Its largest new stake was GE Vernova: 2,330,887 shares worth $400M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Procter & Gamble, an estimated $474M trimmed.
- Marshall Wace's largest Q2 2024 buy was GE Vernova: 2,330,887 shares worth $400M.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q2 2024, an estimated $3.04B increase.
- Marshall Wace's biggest Q2 2024 reduction was Procter & Gamble, cutting an estimated $474M.
- Marshall Wace fully exited Applied Materials in Q2 2024, selling an estimated $127M.
- Marshall Wace's ten largest holdings make up 33% of its $74.9B portfolio in Q2 2024.
- Marshall Wace opened 748 new positions and closed 654 in Q2 2024.
- Marshall Wace's portfolio value rose 14% quarter-over-quarter to $74.9B.
Based on Marshall Wace's 13F filing for Q2 2024, filed 14 Aug 2024.